Breaks Categories: News

TuesdayJun 01, 2021 12:40 pm

BioMedNewsBreaks – InvestorBrandNetwork, BioMedWire to Collaborate with Q1 Productions for Slate of Upcoming Events

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it will collaborate with Q1 Productions as an official media sponsor for its full event lineup in 2021. IBN also announced that BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of the InvestorBrandNetwork, will also be joining as an official media sponsor for Q1 Productions’ upcoming events. Over the past 15 years, Q1 Productions has established a strong reputation specializing in providing high-level educational content through a myriad of conferences, forums, webinars and other services. “We are delighted…

Continue Reading

TuesdayJun 01, 2021 12:30 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Completes Initial Shipment for Major Plant-Based Medicine Trial

RYAH Group (CSE: RYAH) today announced that it has completed the first shipment of the RYAH Smart Dry Herb Inhalers, which includes a delivery of approximately 10,000 RYAH Cartridges and QR Codes to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine. The initial shipment is designated to be used by the clinic in a pilot run in preparation for the previously announced, UK-based study on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. “We are pleased to bring RYAH’s IoT device and…

Continue Reading

WednesdayMay 26, 2021 12:19 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder, CEO Authors Book Focused on Groundbreaking Work

Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach…

Continue Reading

WednesdayMay 26, 2021 12:08 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Initiation of PALISADE Phase 3 Study of PH94B in SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, is beginning its PALISADE-1 phase 3 trial. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of VTGN’s PH94B (“PH94B”) for the treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In the announcement, the company noted there is no FDA-approved acute treatment for the disorder. The company plans to include some 200 randomized subjects in the study, which…

Continue Reading

TuesdayMay 25, 2021 11:11 am

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Ships Devices for Pilot Study with Milan, Italy-Based CLINN

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has completed initial shipment of its proprietary Smart Dose-Measuring inhalers for use in a pilot study conducted by CLINN medical center in Milan, Italy. Per the update, CLINN, the first and only cannabis-specialized clinic in Italy, named the best cannabis clinic in Europe by CanEx, is launching an observation study using RYAH devices in order to collect accurate patient feedback on consumption of cannabis strains available on the Italian market. Italy, with 30% growth over the last year, remains the second-largest market in Europe with more than 20,000 patients, which…

Continue Reading

MondayMay 24, 2021 11:01 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Secures Purchase Order for Its Pediatric NeuroCap(TM) EEG Headsets

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that Maine Medical Center has placed an order for a limited supply of the company’s pediatric NeuroCap(TM) disposable EEG caps for use with its pediatric patients. Maine Medical Center, with a staff of over 6,000, is a 637-licensed-bed teaching hospital for Tufts University School of Medicine. “We are happy to provide our pediatric EEG products to Maine Medical Center. The NeuroCap for children is designed to address the need for comfort, speed and reliability within the pediatric population,” said Amy Griffith, VP Strategy and Business Development for…

Continue Reading

ThursdayMay 20, 2021 12:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Presentation Schedule for June Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the update, at the Jefferies Virtual Healthcare Conference and the William Blair 41st Annual Virtual Growth Stock Conference. Interested parties should visit the sponsor’s conference website for more information regarding these events. To view the full press release, visit https://ibn.fm/lYl1b About VistaGen Therapeutics Inc. VistaGen is…

Continue Reading

ThursdayMay 20, 2021 11:45 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary Covid-ID Lab to Launch in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that Marx Pharma GmbH, the company’s distribution, storage and logistics partner, is launching Covid-ID Lab, XPhyto’s 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system in Germany; the product will launch on May 25. The announcement noted that the proprietary Covid-ID Lab will be priced within the range of commonly available COVID-19 PCR test products already on the market and that initial manufacturing capacity has been determined; additional manufacturing capacity is also available if needed. XPhyto’s Covid-ID Lab requires only a 20-minute PCR run…

Continue Reading

WednesdayMay 19, 2021 10:24 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. “As the process moves forward, we’re creating the potential for additional IP that will…

Continue Reading

WednesdayMay 19, 2021 9:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Patient Enrollment in Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has begun open enrollment for its upcoming study focused on analyzing the efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (“GBM”). GMB is one of the most aggressive types of brain cancer, and Berubicin, which is in development for the treatment of several serious brain and CNS oncology indications, is the first anthracycline to cross the blood-brain barrier. CNSP plans on enrolling some 210 subjects across 35 clinical sites…

Continue Reading